Biomarker: PD-L1

Targeted TherapyApproved for: NSCLCBiomarker: PD-L1 Atezolizumab (Tecentriq) is a FDA-approved treatment for non-small cell lung cancer that has metastasized. It is used: As first-line therapy in adults whose cancer has the PD-L1 protein and does not have a mutation...

Targeted TherapyApproved for: NSCLCBiomarker: PD-L1 Nivolumab (Opdivo/Opdivo Injection) is an FDA-approved treatment for non-small cell lung cancer (NSCLC). It is used: As first-line therapy with ipilimumab in adults whose cancer is metastatic and has the PD-L1 protein but does...